| Literature DB >> 17912368 |
Mark Tarnopolsky1, Andrew Zimmer, Jeremy Paikin, Adeel Safdar, Alissa Aboud, Erin Pearce, Brian Roy, Timothy Doherty.
Abstract
Aging is associated with lower muscle mass and an increase in body fat. We examined whether creatine monohydrate (CrM) and conjugated linoleic acid (CLA) could enhance strength gains and improve body composition (i.e., increase fat-free mass (FFM); decrease body fat) following resistance exercise training in older adults (>65 y). Men (N = 19) and women (N = 20) completed six months of resistance exercise training with CrM (5g/d)+CLA (6g/d) or placebo with randomized, double blind, allocation. Outcomes included: strength and muscular endurance, functional tasks, body composition (DEXA scan), blood tests (lipids, liver function, CK, glucose, systemic inflammation markers (IL-6, C-reactive protein)), urinary markers of compliance (creatine/creatinine), oxidative stress (8-OH-2dG, 8-isoP) and bone resorption (Nu-telopeptides). Exercise training improved all measurements of functional capacity (P<0.05) and strength (P<0.001), with greater improvement for the CrM+CLA group in most measurements of muscular endurance, isokinetic knee extension strength, FFM, and lower fat mass (P<0.05). Plasma creatinine (P<0.05), but not creatinine clearance, increased for CrM+CLA, with no changes in serum CK activity or liver function tests. Together, this data confirms that supervised resistance exercise training is safe and effective for increasing strength in older adults and that a combination of CrM and CLA can enhance some of the beneficial effects of training over a six-month period. Trial Registration. ClinicalTrials.gov NCT00473902.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17912368 PMCID: PMC1994592 DOI: 10.1371/journal.pone.0000991
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Summary of the recruitment strategy and allocation.
Subject Characteristics, Body Composition and Bone Density.
| Placebo | Supplement | |||||||||
| MEN (N = 8) | WOMEN (N = 10) | MEN (N = 11) | WOMEN (N = 10) | Training Effect | Sex Effect | |||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | P value | P value | |
| Age (y) | 74.8±6.6 | NC | 68.3±4.4 | NC | 71.8±5.2 | NC | 69.5±3.8 | NC | NC | 0.01 |
| Height (cm) | 172.1±7.4 | NC | 160.8±6.8 | NC | 171.0±7.4 | NC | 161.1±5.2 | NC | NC | 0.00 |
| Weight (kg) | 76.7±8.2 | 77.2±7.8 | 65.3±10.5 | 65.1±10.2 | 81.6±11 | 81.8±11.6 | 66.2±8.4 | 65.7±8 | 0.98 | 0.0002 |
| FFM (kg) | 55.8±5.5 | 57.2±5.7 | 41.1±5.1 | 41.5±5.1 | 58.1±8.6 | 60.8±8.5 | 41.3±4.4 | 42.9±4.7 | 0.0001 | 0.0001 |
| FM (kg) | 18.8±4.4 | 18.2±4.2 | 22.8±5.7 | 22.6±5.9 | 21.4±4.9 | 19.9±5.9 | 23.5±5.3 | 21.5±5.6 | 0.0001 | 0.08 |
| B.M.I. | 25.9±2.7 | 26.1±2.5 | 25.2±3.0 | 25.1±2.9 | 27.8±2.1 | 27.8±2.1 | 25.5±3.1 | 25.3±3.0 | 0.07 | 0.86 |
| BMD-total | 1.21±0.09 | 1.25±0.11 | 1.13±0.12 | 1.15±0.13 | 1.20±0.13 | 1.23±0.13 | 1.02±0.09 | 1.04±0.08 | 0.34 | 0.0005 |
| BMD-hip | 1.01±0.09 | 0.98±0.08 | 0.86±0.14 | 0.84±0.13 | 0.94±0.10 | 0.92±0.10 | 0.83±0.10 | 0.81±0.11 | 0.0001 | 0.001 |
| BMD-L-spine | 1.12±0.06 | 1.12±0.07 | 1.12±0.15 | 1.11±0.18 | 1.19±0.14 | 1.19±0.15 | 0.94±0.11 | 0.94±0.09 | 0.66 | 0.004 |
Values are means±standard deviation. NC = no change; FFM = fat free mass; FM = fat mass; BMI = body mass index.
indicates a significant interaction between training and supplement (see text).
indicates a significant interaction between men and women in response to training (see text).
Figure 2(A) Changes in fat free mass between supplement groups and sex in response to training.
(B) Changes in fat mass between supplement and sex in response to training. Values are means±standard deviation. *-indicates a significant difference with a p<0.05 (see text).
Dietary Analysis.
| Placebo | Supplement | |||||||||
| MEN (N = 5) | WOMEN (N = 7) | MEN (N = 9) | WOMEN (N = 8) | Training Effect | Sex Effect | |||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | P value | P value | |
| Intake (kcal/d) | 2812±914 | 2777±689 | 1989±178 | 1886±356 | 2435±1108 | 2409±1110 | 1916±466 | 1974±681 | 0.81 | 0.02 |
| % PRO | 16±3 | 16±2 | 16±3 | 17±3 | 15±3 | 16±3 | 17±4 | 17±2 | 0.67 | 0.26 |
| % CHO | 60±4 | 61±10 | 49±10 | 52±11 | 50±6 | 48±5 | 49±10 | 51±6 | 0.48 | 0.14 |
| % FAT | 26±4 | 23±4 | 35±8 | 33±5 | 34±6 | 34±4 | 35±6 | 34±4 | 0.18 | 0.007 |
| PRO (g/kg)/d | 1.3±0.6 | 1.4±0.3 | 1.4±0.4 | 1.2±0.3 | 1.1±0.4 | 1.1±0.3 | 1.2±0.2 | 1.3±0.3 | 0.81 | 0.93 |
| % C2H5OH | 3.7±3.3 | 6.1±2.4 | 3.2±2.9 | 3.3±4.1 | 4.1±4.6 | 5.1±4 | 3.8±3.7 | 3.1±3.4 | 0.21 | 0.27 |
| Ca++ | 1204±387 | 1162±368 | 718±209 | 758±158 | 913±413 | 773±335 | 987±462 | 951±409 | 0.52 | 0.17 |
Values are means±standard deviation. PRO = protein; CHO = carbohydrate; C2H5OH = ethanol; Ca++ = calcium.
Muscle Strength Tests.
| Placebo | Supplement | |||||||||
| MEN (N = 8) | WOMEN (N = 10) | MEN (N = 10) | WOMEN (N = 10) | Training Effect | Sex Effect | |||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | P value | P value | |
| Isometric | ||||||||||
| Knee Ext.(Nm) | 133.9±37.3 | 152.0±44.7 | 78.6±12.6 | 96.0±20.2 | 135.8±37.4 | 151.4±52.4 | 86.0±14.3 | 105.6±17.8 | 0.0001 | 0.0001 |
| Dorsiflexion(Nm) | 56.7±14.9 | 55.9±14.4 | 35.5±4.6 | 37.3±5.2 | 48.8±10.9 | 54.7±12.7 | 30.4±5.2 | 34.1±7.6 | 0.03 | 0.0001 |
| Jamar (kg) | 39±6 | 42±6 | 25±4 | 27±4 | 39±7 | 43±7 | 27±5 | 30±4 | 0.0001 | 0.0001 |
| Isokinetic | ||||||||||
| Knee 120 deg/sec | 93.1±26.7 | 101.3±23.4 | 53.2±20.2 | 64.7±9.2 | 88.2±27.2 | 108.2±26.2 | 57.7±16.4 | 68.0±15. 5 | 0.0001 | 0.0001 |
| 1 Repetition Maximum (lb) | ||||||||||
| Chest Press | 98±23 | 136±16 | 60±12 | 91±9 | 104±35 | 146±38 | 53±7 | 89±15 | 0.0001 | 0.0001 |
| Arm Flexion | 64±17 | 104±23 | 32±9 | 57±11 | 76±35 | 115±36 | 29±7 | 61±16 | 0.0001 | 0.0001 |
| Leg Press | 205±55 | 269±52 | 137±33 | 187±54 | 215±59 | 295±74 | 123±22 | 200±31 | 0.0002 | 0.0001 |
| Knee Extension | 106±20 | 158±31 | 81±27 | 109±13 | 117±39 | 163±44 | 64±16 | 113±18 | 0.0001 | 0.0001 |
| Endurance (lb) | ||||||||||
| Chest Press | 1±0 | 17±11 | 1±0 | 18±6 | 1±0 | 22±10 | 1±0 | 32±11 | 0.0001 | 0.12 |
| Arm Flexion | 1±0 | 16±7 | 1±0 | 15±9 | 1±0 | 21±12 | 1±0 | 25±9 | 0.0001 | 0.56 |
| Leg Press | 1±0 | 21±16 | 1±0 | 27±12 | 1±0 | 27±13 | 1±0 | 46±27 | 0.0001 | 0.07 |
| Knee Extension | 1±0 | 17±8 | 1±0 | 10±2 | 1±0 | 14±4 | 1±0 | 17±6 | 0.0001 | 0.38 |
Values are means±standard deviation. RM = repetition maximum.
indicates a significant interaction between training and supplement (see text).
indicates a significant interaction between training, supplement and gender (see text).
Functional Tests.
| Placebo | Supplement | |||||||||
| MEN (N = 8) | WOMEN (N = 10) | MEN (N = 11) | WOMEN (N = 10) | Training Effect | Sex Effect | |||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | P value | P value | |
| Sit and Stand (#) | 13±2 | 16±1 | 10±2 | 14±4 | 12±2 | 15±3 | 11±3 | 13±2 | 0.0001 | 0.0005 |
| Timed Stairs (sec) | 6.8±0.6 | 6.9±1.5 | 8.7±1.7 | 8.1±1.6 | 8.1±1.3 | 7.7±1.5 | 7.8±0.9 | 6.9±0.9 | 0.004 | 0.24 |
| Walk Test (sec) | 14.8±2.7 | 13.7±2.1 | 17.5±2.5 | 16.1±2.4 | 17.3±2.6 | 16.6±3.5 | 16.8±2.0 | 15.1±1.2 | 0.0001 | 0.34 |
| Chair and Walk (sec) | 13.4±1.7 | 11.4±2.3 | 15.0±2.4 | 13.3±2.2 | 14.5±2.4 | 13.7±3.1 | 14.3±2.1 | 12.6±1.3 | 0.0001 | 0.08 |
| Balance Walk (sec) | 23.4±8.5 | 22.3±9.0 | 33±6.1 | 28.1±7.6 | 32.6±11.4 | 27.4±8.1 | 31.9±8 | 25.3±7.8 | 0.04 | 0.04 |
Values are means±standard deviation. Sec = seconds; # = number completed.
Blood Analysis.
| Placebo | Supplement | |||||||||
| MEN (N = 8) | WOMEN (N = 10) | MEN (N = 11) | WOMEN (N = 10) | Training Effect | Sex Effect | |||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | P value | P value | |
| Glucose (mmol/L) | 4.8±0.5 | 4.8± 0.5 | 4.6±0.5 | 4.8±0.8 | 5.0±0.6 | 4.9± 1.70 | 4.9±0.5 | 4.7±0.6 | 0.89 | 0.63 |
| HOMA-IR | 1.53±1.01 | 1.36±0.66 | 0.76±0.59 | 1.28±1.46 | 1.54±1.36 | 1.23±0.99 | 1.43±1.01 | 0.94±0.35 | 0.50 | 0.34 |
| CK (µmol/L) | 90.1±26.9 | 113.8±29.8 | 103.3±31.7 | 120.3±38.6 | 114.8±50.1 | 180.3±120.5 | 146.0±153.3 | 187.7±181.7 | 0.0001 | 0.78 |
| Bili (µmol/L) | 9.3±2.9 | 10.6±2.3 | 7.5±2.2 | 7.5±1.5 | 10.5±3.9 | 11.6±6.0 | 7.5±3.0 | 7.8±2.4 | 0.17 | 0.02 |
| GGT (µmol/L) | 26.4±7.9 | 25.5±4.9 | 27.3±17.0 | 26.6±12.4 | 30.5±22.5 | 27.8±22.3 | 21.2±12.8 | 22.6±5.9 | 0.90 | 0.90 |
| Crn (µmol/L) | 87±10 | 86±6 | 71±10 | 70±14 | 90±19 | 114±25 | 71±11 | 80±17 | 0.0001 | 0.0001 |
| LDL (mmol/L) | 3.03±0.56 | 3.33±0.75 | 3.27±1.08 | 3.46±1.19 | 3.14±0.45 | 3.33±0.54 | 3.20±0.96 | 3.54±0.85 | 0.002 | 0.83 |
| HDL (mmol/L) | 1.57±0.32 | 1.63±0.39 | 2.07±0.45 | 2.22±0.59 | 1.32±0.28 | 1.34±0.21 | 1.82±0.31 | 1.83±0.37 | 0.09 | 0.0001 |
| Chol (mmol/L) | 5.35±0.57 | 5.68±0.85 | 5.96±1.16 | 6.32±1.38 | 5.37±0.51 | 5.54±0.72 | 5.68±1.09 | 6.13±1.00 | 0.0007 | 0.23 |
| LDL/HDL (mmol/L) | 2.02±0.59 | 2.19±0.81 | 1.65±0.68 | 1.62±0.62 | 2.47±0.62 | 2.54±0.59 | 1.84±0.79 | 2.02±0.72 | 0.097 | 0.018 |
| Leptin (ng/mL) | 4.54±1.87 | 4.84±2.26 | 16.0±10.26 | 15.33±9.61 | 4.84±2.47 | 4.38±3.70 | 16.21±12.74 | 16.95±15.97 | 0.97 | 0.0003 |
| CRP (mg/L) | 2.98±3.24 | 1.85±1.05 | 3.65±3.62 | 3.80±4.25 | 2.56±3.12 | 3.79±4.33 | 3.31±3.5 | 5.12±3.47 | 0.44 | 0.23 |
| Adipon. (mg/L) | 9.65±4.33 | 10.32±3.96 | 17.12±7.54 | 16.47±6.33 | 7.18±4.39 | 6.48±3.19 | 12.89±5.84 | 13.72±7.1 | 0.96 | 0.0003 |
| IL-6 (pg/mL) | 2.38±3.2 | 2.33±2.21 | 3.91±3.03 | 4.06±3.05 | 5.48±3.08 | 7.3±4.47 | 1.81±1.46 | 2.04±.82 | 0.10 | 0.61 |
Values are means±standard deviation. HOMA-IR = homeostasis model assessment of insulin resistance; CK = creatine kinase; billi = bilirubin; GGT = gamma glutamyl transferase; LDL = low density lipoprotein; HDL = high density lipoprotein; Chol = total cholesterol; CRP = C-reactive protein; Adipon. = adiponectin; IL-6 = interleukin -6.
indicates a significant interaction between training and supplement (see text).
Urine Analysis.
| Placebo | Supplement | |||||||||
| MEN | WOMEN | MEN | WOMEN | Training Effect | Sex Effect | |||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | P value | P value | |
| Cr (mg/24 hr) | 43.7±51.8 | 31.9±39.7 | 150±128.1 | 181.3±145.5 | 66±62.6 | 1851.1± 933.5 | 171.4±153.9 | 2393.7± 1656 | 0.0002 | 0.11 |
| Crn (mg/24 hr) | 1265.6±284.0 | 1293.2±217.0 | 978.3±258.2 | 979.0±123.8 | 1432.1±363.2 | 1808.0±544.0 | 935.9±158.8 | 1034.1± 31.6 | 0.002 | 0.0001 |
| Crn Cl. (mL/sec) | 1.51±0.36 | 1.54±0.32 | 1.44±0.44 | 1.49±0.36 | 1.72±0.65 | 1.70±0.71 | 1.39±0.33 | 1.40±0.45 | 0.73 | 0.21 |
| Cr/Crn ratio | 0.04±0.05 | 0.02±0.03 | 0.16±0.14 | 0.19±0.17 | 0.05±0.06 | 1.11±1.24 | 0.18±0.16 | 2.24±1.52 | 0.0003 | 0.009 |
| 8-OH/Crn (ng/g Crn) | 8329±3032 | 7394±1921 | 11622±4379 | 10713±3190 | 7245±2703 | 6130±1260 | 7942±3071 | 7088±2582 | 0.01 | 0.03 |
| 8-iso/Crn (pg/mg Crn) | 2.9±1.3 | 3.8±1.0 | 3.8±1.3 | 4.1±2.1 | 2.5±2.2 | 2.3±1.4 | 5.2±2.3 | 9.9±6.2 | 0.03 | 0.005 |
|
| 380.6±335.7 | 378.1±275.6 | 354.7±231.3 | 235.9±146.5 | 510±353.3 | 712.4±714.4 | 257.7±79.7 | 272.1±154.2 | 0.67 | 0.09 |
Values are means±standard deviation. 8-OH = 8-hydroxy-2-deoxyguanosine; 8-Iso. = 8-isoprostane per 24 hour urine; Cr = Creatine; Crn = creatinine; Cl. = Clearance; N-telo = N-telopeptides; BCE = bone collagen equivalent.
indicates a significant interaction between training and supplement (see text).
indicates a significant interaction between training, supplement and gender (see text).